Clinical Trial Update: A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating PD0332991 (palbociclib) as a selective CDK4/6 inhibitor in recurrent ovarian cancer with RB-proficiency and low p16 expressi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Epithelial Cancer

Drugs mentioned

• PD0332991 (palbociclib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Ovarian Epithelial Carcinoma | Phase 2 | Status: COMPLETED